Promising discovery in the fight against neurodegenerative diseases: a molecule that stops cell death

Australian researchers have identified a compound that can block the process of cell death, opening new prospects for treatments against Parkinson's and Alzheimer's disease. A group of researchers from the Walter & Eliza Hall Medical Research Institute (WEHI) in Melbourne, Australia, announced a discovery with revolutionary potential in the treatment of neurodegenerative diseases, reports Xinhua news agency. A small molecule discovered by the research team manages to block the action of a key protein involved in the death of nerve cells, a phenomenon essential in the development of diseases such as Parkinson's and Alzheimer's.

• A precise molecular target: the BAX protein

The BAX protein, also called the "killer cell", is known for its essential role in triggering programmed cell death (apoptosis), especially in neurons affected by degenerative processes. Blocking this protein could prevent damage to mitochondria - the cellular structures responsible for energy production - allowing the affected neurons to survive. "Currently, there are no treatments that prevent the death of neurons to slow the progression of Parkinson's disease. Any drug that could do this would be revolutionary," said Grant Dewson, director of the Parkinson's Disease Research Center at WEHI.

• Large-scale screening and published results

The discovery was made as part of an intensive screening program conducted at the National Drug Discovery Center at WEHI. The researchers analyzed more than 100,000 chemical compounds, identifying a substance with the ability to inhibit the destructive activity of the BAX protein. The results were published in the journal Science Advances, and the study's lead author, Li Kaiming, highlighted the huge potential of the discovery: "This molecule could pave the way for a new generation of cell death inhibitors targeted for the treatment of degenerative diseases," the researcher said.

• Hope for future treatments

The WEHI Institute, founded more than a century ago and known for its contributions to cancer research, now aims to develop neuroprotective therapies. The new directions aim at treatments that slow or even stop neuronal degeneration in conditions for which current medicine only offers symptomatic solutions.

Although the research is in its early stages and requires years of preclinical and clinical testing, specialists consider this to be one of the most promising discoveries in the field of neuroscience in the last decade.